重新启动研究:一组腹部迷走神经刺激的单一组,开放标签安全研究中等至重度药物难治性类风湿关节炎 (Reboot)
This open label clinical trial aims to assess the safety of abdominal vagus nerve stimulation (aVNS) for moderate to severe, adult-onset rheumatoid arthritis (RA) that has not responded to medication. The aVNS is an active medical device placed into the body to allow electrical stimulation of the abdominal vagus nerve. Participants will undergo stimulation treatment with the aVNS device from two to 24 weeks after the device is implanted by keyhole surgery. Safety, device performance and potential benefits will be assessed. Participants will be monitored for specific events for 5 years post surgery.
研究概览
详细说明
This open label first-in-indication study will assess safety of an abdominal vagus nerve stimulation (aVNS) device in 5 adult participants with moderate to severe drug refractory rheumatoid arthritis (RA). The trial primary objectives at 24 weeks are to assess: 1) safety of aVNS and; 2) device performance. An exploratory objective is to assess non-futile benefits of aVNS at 12 and 24 weeks. During the initial phase of the study (2-24 weeks), stimulation will be delivered for 3 hours per day, with the participant switching the device on and off via a controller. Reports of safety, device checks and clinical assessment of RA symptoms will occur during at 2-, 6-, 12- and 24-weeks post-surgery. Participants that complete the initial phase of the study (24 week assessment) will have the option to continue using the device. Participants that do not want to continue treatment, or withdraw, will have their device deactivated. The device will remain implanted unless there is a clinical reason to remove it or if the participant requests removal. During the follow up phase of the safety trial (24-265 weeks), participants will be monitored twice a year for up to 5 years. The total duration of involvement of participants will be approximately 5 years.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:A/Prof Shereen Oon, MBBS, PhD
- 电话号码:+61392311203
- 邮箱:rheumclintrials@svha.org.au
研究联系人备份
- 姓名:Angela Chia, RN
- 电话号码:+61392311203
- 邮箱:rheumclintrials@svha.org.au
学习地点
-
-
Victoria
-
Fitzroy、Victoria、澳大利亚、3065
- 招聘中
- Bionics Institute
-
Fitzroy、Victoria、澳大利亚、3065
- 招聘中
- St Vincent's Hospital, Department of Rheumatology
-
Ivanhoe、Victoria、澳大利亚、3079
- 招聘中
- Austin Health, Heidelberg Repatriation Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female (18 - 75 years of age).
- Adult-onset rheumatoid arthritis (RA) (onset age 18 years or above) as defined by the 2010 ACR/EULAR classification criteria, and Rheumatoid Factor (RF) or Cyclic Citrullinated Peptide (CCP) Antibody/Anti-Citrullinated Peptide Antibody (ACPA) must be positive (above lab ranges).
- Moderate-severe active RA defined by at least 4/28 tender and 4/28 swollen joints.
- Have active disease that has not responded to a 3-month trial of, or has intolerance limiting a full 3 month trial of, at least 2 biologic and/or new targeted synthetic DMARDs (e.g. JAK inhibitors).
- Using a stable, continuous dose of at least 1 biological and/or synthetic DMARD for >8 weeks prior to study screening and for the duration of the trial.
- Women of childbearing age must not be pregnant or trying to become pregnant and must agree to use an effective method of contraception for the duration of their participation in the trial.
- Medicare eligibility.
- Provision of informed consent, in the form of a signed and dated informed consent form.
Exclusion Criteria:
- Unable or unwilling to provide written informed consent.
- Current diagnosis of major psychiatric disorder/s, or meets criteria as such on the Mini International Neuropsychiatric Interview (MINI), with the exception of stable, well controlled Major Depression or Anxiety Disorder.
- A medical condition that could interfere with study procedures, and/or confound evaluation of study endpoints, as determined by the Investigator.
- Medical conditions that have resulted in severe autonomic neuropathy e.g. poorly controlled type 2 diabetes or metabolic disease.
- History of previous surgical interventions including vagotomy, splenectomy, bariatric surgery.
- History of gastric hiatus hernia.
- Previously implanted active medical devices (e.g., dorsal root ganglion or spinal cord stimulators, cardiac pacemakers, automatic implantable cardioverter-defibrillators, drug pumps), or likely need for implantation of such devices within 6 months after start of this study.
- A condition that requires routine Magnetic Resonance Imaging (MRI) scans
- Is, in the opinion of the Principal Investigator/s not a suitable candidate for the trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:abdominal vagus nerve stimulation (aVNS)
Participants will receive aVNS, delivered by the implanted aVNS device. |
Participants will receive aVNS, delivered by a commercially available stimulator placed under the skin, and a custom-designed electrode array attached to the abdominal vagus nerve. Stimulation will commence 2 weeks after laparoscopic surgical implantation of the device, and occur daily for 22-weeks stimulation in the initial phase of the study.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.
大体时间:24 weeks
|
Rate of recorded Serious Adverse Device Effects (SADEs) less than that for the Evoke® device (2%), a commercially available, FDA approved, CE marked implantable spinal cord stimulator. |
24 weeks
|
|
Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.
大体时间:24 weeks
|
No significant increase in electrically Evoked Compound Action Potentials (ECAPs) threshold |
24 weeks
|
|
Safety of aVNS in individuals with drug refractory moderate-severe adult-onset RA.
大体时间:24 weeks
|
No significant decrease in amplitude of electrically Evoked Compound Action Potentials (ECAPs) |
24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Performance of the aVNS System.
大体时间:24 weeks
|
Rate of device deficiencies less than that for the Evoke® device |
24 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Exploratory Outcome: Non-futile benefits of aVNS in individuals with drug refractory moderate-severe adult-onset RA.
大体时间:Baseline to week 6, 12 or 24 assessment.
|
ACR 20, 50 or 70 response rates in DAS28-CRP from pre-surgery baseline levels. |
Baseline to week 6, 12 or 24 assessment.
|
合作者和调查者
调查人员
- 首席研究员:A/Prof Shereen Oon、St Vincent's Hospital Melbourne
出版物和有用的链接
一般刊物
- Payne, S. C., Burns, O., Stebbing, M., Thomas, R., Silva, A. de, Sedo, A., … Shepherd, R. K. (2018). Vagus Nerve Stimulation to Treat Inflammatory Bowel Disease: A Chronic, Preclinical Safety Study in Sheep. Bioelectronics in Medicine, 1(4), 235-250. https://doi.org/10.2217/bem-2018-0011
- Payne SC, Furness JB, Stebbing MJ. Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms. Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):89-105. doi: 10.1038/s41575-018-0078-6.
- Payne SC, Furness JB, Burns O, Sedo A, Hyakumura T, Shepherd RK, Fallon JB. Anti-inflammatory Effects of Abdominal Vagus Nerve Stimulation on Experimental Intestinal Inflammation. Front Neurosci. 2019 May 8;13:418. doi: 10.3389/fnins.2019.00418. eCollection 2019.
- Payne SC, Romas E, Hyakumura T, Muntz F, Fallon JB. Abdominal vagus nerve stimulation alleviates collagen-induced arthritis in rats. Front Neurosci. 2022 Nov 21;16:1012133. doi: 10.3389/fnins.2022.1012133. eCollection 2022.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.